Impact of Oral Carbohydrate Consumption Prior to Cesarean Section

July 30, 2019 updated by: University of Florida

Impact of Oral Carbohydrate Consumption Prior to Cesarean Section on Preoperative Well-being

For more than 15 years, traditional fasting regimens prior to scheduled surgeries have been called into question, yet prolonged preoperative fasting remains common practice. While prolonged fasting is aimed at reducing the risk of pulmonary aspiration, prolonged fasting is uncomfortable, has an inconsistent effect on gastric volumes and acidity and may lead to dehydration without a clear reduction in the incidence of aspiration. Fasting by itself decreases hepatic glycogen stores, induces a state of insulin resistance and impairs cardiovascular function. Yet, prolonged preoperative fasting remains common.

Preoperative oral carbohydrate (CHO) consumption improves insulin sensitivity and decreases the time to return of gut function without increasing gastric volumes or acidity compared to other clear liquids and fasting. Previous work has shown oral CHO consumption improves patient well-being to a greater degree than placebo drink (water or flavored water) and fasted controls. Oral CHO also outperforms a similar volume of intravenous glucose supplementation. These benefits have reduced hospital stays in a variety of surgical models by as much as 20%. Further, preoperative CHO supplementation improved postoperative patient hunger, thirst, anxiety, fatigue and nausea.

The purpose of this research study is to determine if drinking a high carbohydrate beverage before cesarean section surgery can improve patient well-being, compared to patients who drink a low carbohydrate beverage or fast before surgery.

Study Overview

Detailed Description

The study hopes to determine if either of two different oral beverages (a higher CHO concentration versus a lower CHO concentration) is superior to routine fasting in terms of preoperative well-being among patients presenting for scheduled cesarean section. Preoperative well-being will be determined by a composite of visual analog scale scores aimed at assessing hunger, thirst, anxiety, fatigue and nausea on the morning of surgery.

Women will be recruited from one of two outpatient obstetric clinics, University of Florida (UF) Health Women's Center - Medical Plaza or UF Health Women's Center. Women presenting for scheduled cesarean section will be provided with an opportunity to participate. Then the women will be randomized into one of three groups: oral carbohydrate beverage (group CHO), re-hydration beverage of an equal volume (group R) or fasted controls (group F). All subjects who consent to participation will have the following recorded: height, weight, age, indication for cesarean section, surgeon, and number of prior cesarean sections.

Study Type

Interventional

Enrollment (Actual)

134

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Gainesville, Florida, United States, 32610-3003
        • UF Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Full-term (≥37 weeks gestation) with singleton gestation
  • Proficient with English language
  • Planning on undergoing scheduled cesarean delivery under neuraxial anesthesia

Exclusion Criteria:

  • Women with pre-gestational or gestational diabetes mellitus or diabetes present prior to pregnancy
  • Women who did not complete a gestational diabetes screening test
  • Women who received steroids within the past 7 days prior to delivery
  • Women who received magnesium sulfate in the setting of hypertensive disorders of pregnancy
  • Women with a history of chronic opioid use
  • Preterm pregnancies
  • Fetuses with congenital abnormalities or growth restriction
  • Multiple gestation
  • Women who are American Society of Anesthesiology Class III or higher

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Oral Carbohydrate Beverage Group
Subjects assigned to this group will receive 710 mL of a preoperative beverage the evening prior to surgery and 355 mL the morning of surgery.
The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
Other Names:
  • Preoperative beverage
Active Comparator: Rehydration Beverage Group
Subjects assigned to this group will receive 710 mL of re-hydration beverage the evening prior to surgery and 355 mL the morning of surgery.
The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
Other Names:
  • Preoperative beverage
No Intervention: Fasted Controls
Subjects assigned to this group will fast for ≥8 hours prior to surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in preoperative well-being assessment from baseline to one hour using the 100 millimeter (mm) visual analogue scale.
Time Frame: Change from baseline to one hour
100 mm visual analogue scales for hunger, thirst, anxiety, fatigue and nausea administered on the morning of surgery prior to morning beverage consumption and 60 minutes after the beverage. All measurements will be assessed using the same scale starting at 0 to 100mm with 0 being the worst and 100 being the best and average being 85.
Change from baseline to one hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes between the maternal groups assessed by the mean arterial pressure (MAP) recordings in every 5 minute period
Time Frame: At time of surgery to the conclusion
Maternal cardiovascular function will be assessed by using the average of all the mean arterial pressure (MAP) recordings in every 5 minute period. This will be measured by using a student's t-test for significant differences between the groups.
At time of surgery to the conclusion
Number of participants admitted to maternal intensive care unit between the groups
Time Frame: Up to 15 days
Number of ICU admissions during hospitalization between the groups
Up to 15 days
Number of days in the hospital for each participant between the groups
Time Frame: Up to 15 days
Number of days in the hospital for each participant between the groups. This will be measured by using the chi-square tests to assess the frequency of this outcome between the groups.
Up to 15 days
Number of postoperative infections between the groups
Time Frame: Up to 15 days
Number of postoperative infections for each participant between the groups. This will be measured by using the chi-square tests to assess the frequency of this outcome between the groups.
Up to 15 days
Neonates with plasma glucose level of less than 45 mg/dL between the groups
Time Frame: Baseline
First umbilical cord blood sample will be taken for plasma glucose level of less than 45 mg/dL to note hypoglycemia between the groups.
Baseline
Number of neonates with a 5 minute Apgar score less than 7 between the groups
Time Frame: 5 minutes
Record of the 5 minute apgar score < 7. Apgar scores are as follows: between 7 and 10, means the neonate is in good shape, between 4 and 6 may need some help breathing, and 3 or less may need immediate lifesaving measures.
5 minutes
Number of neonates on ventilation for 6 hours or greater between the groups
Time Frame: 6 hours
Number of neonates on ventilation for 6 hours or greater will be recorded.
6 hours
Number of neonates diagnosed with an infection between the groups.
Time Frame: Baseline
Number of neonates with an infection diagnosis. This will be measured by using the chi-square tests to assess the frequency of this outcome between the groups.
Baseline
Number of neonates admitted to the intensive care unit (ICU) between the groups
Time Frame: Baseline
Number of neonates admitted to the ICU between the groups. This will be measured by using the chi-square tests to assess the frequency of this outcome between the groups.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Adam Wendling, MD, University of Florida

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 14, 2016

Primary Completion (Actual)

June 12, 2018

Study Completion (Actual)

April 4, 2019

Study Registration Dates

First Submitted

February 4, 2016

First Submitted That Met QC Criteria

February 12, 2016

First Posted (Estimate)

February 18, 2016

Study Record Updates

Last Update Posted (Actual)

July 31, 2019

Last Update Submitted That Met QC Criteria

July 30, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dehydration

Clinical Trials on Oral Carbohydrate Beverage

3
Subscribe